• Northeast Georgia Health System becomes Artrya's second US commercial customer
• Three-year commercial agreement with minimum value of US$0.3M
• Salix® platform to be rolled out across NGHS network and used by Georgia Heart Institute

Artrya Limited (ASX: AYA), a medical technology company commercialising its Salix® AI-powered cloud platform, has secured its second US commercial customer with the signing of a three-year commercial agreement with Northeast Georgia Health System (NGHS). Under the contract, the Salix® Coronary Anatomy platform will be licensed as a SaaS platform with a fixed monthly subscription fee, while the Salix® Coronary Plaque module will generate fee-per-scan revenue. The Salix® Coronary Flow module will also be available for clinical use upon FDA clearance. The agreement follows a period of close collaboration between Artrya and NGHS to validate and integrate the Salix® platform into the health system's clinical workflow, including seamless interaction with PACS and EMR systems. NGHS is a leading not-for-profit health network with more than 1.6 million patient visits annually, comprising five hospitals and an extensive network of outpatient facilities. The Salix® platform will now be used in routine care for patients with suspected or confirmed coronary artery disease undergoing CT angiography, across NGHS's hospitals, outpatient centres, and physician practices within the Georgia Heart Institute. To support its growing US customer base and anticipated expansion, Artrya has established a Customer Success team in Atlanta to provide technical integration expertise, clinician engagement, and comprehensive customer support.